Joanne van Ryn

Summary

Affiliation: Boehringer Ingelheim

Publications

  1. doi request reprint Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity
    Joanne van Ryn
    Department of Drug Discovery Support, Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany
    Thromb Haemost 103:1116-27. 2010
  2. doi request reprint Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays
    Joanne van Ryn
    Department of Cardiometabolic Disease Research, Boehringer Ingelheim Pharma GmbH and Co KG, Birkendorfer Street 65, Biberach 88397, Germany Electronic address
    Clin Lab Med 34:479-501. 2014
  3. pmc The discovery of dabigatran etexilate
    Joanne van Ryn
    Department of Cardiometabolic Disease Research, Boehringer Ingelheim Pharma GmbH and Co KG Biberach an der Riss, Baden Wurttemberg, Germany
    Front Pharmacol 4:12. 2013
  4. doi request reprint Interpretation of point-of-care INR results in patients treated with dabigatran
    Joanne van Ryn
    Department of Cardiometabolic Disease Research, Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany
    Am J Med 125:417-20. 2012
  5. doi request reprint Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification
    Andreas Clemens
    Boehringer Ingelheim Pharma GmbH and Co KG, Ingelheim, Germany
    Curr Med Res Opin 28:195-201. 2012
  6. doi request reprint Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation
    Joanne van Ryn
    From the Department of CardioMetabolic Disease Research, Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany J v R, J S, M K E and Department of Global Clinical Development and Medical Affairs, Boehringer Ingelheim Pharma GmbH and Co KG, Ingelheim am Rhein, Germany A C
    Anesthesiology 120:1429-40. 2014
  7. doi request reprint Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial
    Stephan Glund
    Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riß, Germany Electronic address
    Lancet 386:680-90. 2015

Collaborators

Detail Information

Publications7

  1. doi request reprint Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity
    Joanne van Ryn
    Department of Drug Discovery Support, Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany
    Thromb Haemost 103:1116-27. 2010
    ....
  2. doi request reprint Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays
    Joanne van Ryn
    Department of Cardiometabolic Disease Research, Boehringer Ingelheim Pharma GmbH and Co KG, Birkendorfer Street 65, Biberach 88397, Germany Electronic address
    Clin Lab Med 34:479-501. 2014
    ..In addition, the thrombin generation assay is discussed as an important method to determine the potential risk of thrombosis or bleeding and its relevance to the measurement of direct thrombin inhibitors. ..
  3. pmc The discovery of dabigatran etexilate
    Joanne van Ryn
    Department of Cardiometabolic Disease Research, Boehringer Ingelheim Pharma GmbH and Co KG Biberach an der Riss, Baden Wurttemberg, Germany
    Front Pharmacol 4:12. 2013
    ....
  4. doi request reprint Interpretation of point-of-care INR results in patients treated with dabigatran
    Joanne van Ryn
    Department of Cardiometabolic Disease Research, Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany
    Am J Med 125:417-20. 2012
    ..However, case reports have identified falsely elevated point-of-care INR levels in patients treated with dabigatran using one of these devices (Hemochron). This in vitro study was designed to verify this issue...
  5. doi request reprint Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification
    Andreas Clemens
    Boehringer Ingelheim Pharma GmbH and Co KG, Ingelheim, Germany
    Curr Med Res Opin 28:195-201. 2012
    ..Based on its pharmacokinetic profile, dabigatran is dosed twice daily. This analysis provides a quantitative rationale for the selection of the dose regimen in this population...
  6. doi request reprint Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation
    Joanne van Ryn
    From the Department of CardioMetabolic Disease Research, Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany J v R, J S, M K E and Department of Global Clinical Development and Medical Affairs, Boehringer Ingelheim Pharma GmbH and Co KG, Ingelheim am Rhein, Germany A C
    Anesthesiology 120:1429-40. 2014
    ..Dabigatran is a potent oral anticoagulant. Like any anticoagulant, there is an increased risk of bleeding associated with its use, and reversal may be needed in cases of severe bleeding...
  7. doi request reprint Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial
    Stephan Glund
    Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riß, Germany Electronic address
    Lancet 386:680-90. 2015
    ..Here we present the results of the proof-of-concept part of the study...